S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
Log in

OTCMKTS:TPIY - Tianyin Pharmaceutical Stock Price, Forecast & News

$0.0001
0.00 (0.00 %)
(As of 07/15/2019)
Today's Range
$0.00
Now: $0.00
$0.00
50-Day Range N/A
52-Week Range
$0.00
Now: $0.00
$0.02
Volume89,000 shs
Average Volume89,000 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta54.39
Tianyin Pharmaceutical Co., Inc. is engaged in the development, manufacturing, marketing and sale of modernized traditional Chinese medicines and other pharmaceuticals in China. Its products address significant medical needs in the therapeutic areas spanning internal medicines, gynecology, hepatology, otolaryngology, urology, neurology, gastroenterology, orthopedics, dermatology and pediatrics. The company was founded on August 20, 2002 and is headquartered in Chengdu, China.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:TPIY
Previous SymbolNYSEMKT:TPI
CUSIPN/A
Phone00-86-028-8551-6696

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive TPIY News and Ratings via Email

Sign-up to receive the latest news and ratings for TPIY and its competitors with MarketBeat's FREE daily newsletter.


Tianyin Pharmaceutical (OTCMKTS:TPIY) Frequently Asked Questions

What is Tianyin Pharmaceutical's stock symbol?

Tianyin Pharmaceutical trades on the OTCMKTS under the ticker symbol "TPIY."

Has Tianyin Pharmaceutical been receiving favorable news coverage?

Media headlines about TPIY stock have trended positive on Friday, according to InfoTrie. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Tianyin Pharmaceutical earned a daily sentiment score of 2.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Tianyin Pharmaceutical.

Who are some of Tianyin Pharmaceutical's key competitors?

Who are Tianyin Pharmaceutical's key executives?

Tianyin Pharmaceutical's management team includes the folowing people:
  • Guo Qing Jiang, Chairman, President & Chief Executive Officer
  • Tao Yang, Chief Operating Officer
  • Li Ying Wang, Financial Controller
  • Ying Zhang, Director-Human Resources

How do I buy shares of Tianyin Pharmaceutical?

Shares of TPIY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Tianyin Pharmaceutical's stock price today?

One share of TPIY stock can currently be purchased for approximately $0.00.

What is Tianyin Pharmaceutical's official website?

The official website for Tianyin Pharmaceutical is http://www.tianyinpharma.com/.

How can I contact Tianyin Pharmaceutical?

Tianyin Pharmaceutical's mailing address is 23RD FLOOR UNIONSUN YANGKUO PLAZA NO.2 BLOCK 3 RENMIN ROAD SOUTH, CHENGDU P.R. F4, 610041. The company can be reached via phone at 00-86-028-8551-6696 or via email at [email protected]


MarketBeat Community Rating for Tianyin Pharmaceutical (OTCMKTS TPIY)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  64 (Vote Outperform)
Underperform Votes:  43 (Vote Underperform)
Total Votes:  107
MarketBeat's community ratings are surveys of what our community members think about Tianyin Pharmaceutical and other stocks. Vote "Outperform" if you believe TPIY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TPIY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2019 by MarketBeat.com Staff

Featured Article: What is Depreciation?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel